Latest Headlines

  1. Minaris Joins CIRM Industry Resource Partner Program 2/24/2026

    Minaris, a global cell and gene therapy (CGT) contract development and manufacturing organization (CDMO) and multimodality biosafety testing provider, today announced that it has joined the California Institute for Regenerative Medicine (CIRM) Industry Resource Partner (IRP) Program.

  2. Johnson & Johnson Announces $1 Billion Investment With New Cell Therapy Manufacturing Facility In Pennsylvania 2/22/2026

    ohnson & Johnson (NYSE: JNJ) (the “Company”), healthcare’s leading, most comprehensive innovation powerhouse, today announced a more than $1 billion investment in a next generation cell therapy manufacturing facility in Montgomery County, Pennsylvania. This new facility will further expand the Company’s U.S. manufacturing capacity as it advances its industry leading portfolio and pipeline of transformational medicines for cancer, immune-mediated and neurological diseases.

  3. Esco Philippines Returns To The 41st PSNM Annual Convention: Supporting Innovation In Nuclear Medicine 2/19/2026
  4. Nucleus Biologics Launches Krakatoa® K500: A Pod-Based, On-Demand Media And Buffer Manufacturing System Transforming Scale Bioproduction 2/13/2026

    Nucleus Biologics announces the launch of Krakatoa® K500, the first bioreactor-scale, pod-based media and buffer manufacturing system designed to deliver sterile solutions on demand and at point-of-use.

  5. Subcutaneously Administered Nanotrastuzumab Matches Performance Of Herceptin HYLECTA In Minipig Study 2/12/2026

    Nanoform Finland Plc, the medicine performance-enhancing company, announced the results from a preclinical study designed to compare the tolerability and pharmacokinetics of Nanotratsuzumab, a nanoformed, novel, hyaluronidase-free, non-aqueous nanoparticle suspension of trastuzumab for subcutaneous delivery versus Herceptin HYLECTA™, a co-formulated product with Halozyme’s proprietary hyaluronidase enzyme marketed by Roche/Genentech.

  6. Axion BioSystems Acquires High-Throughput, High-Density CMOS MEA Technology From CytoTronics 2/4/2026

    Next-generation CMOS MEA chip technology acquired by Axion BioSystems integrates over 13 million nanoscale multimodal electrode-based sensors distributed across industry-standard 96- or 384-well microplates, enabling high-throughput, single-cell–level functional screening for disease research and drug discovery.

  7. Cellares Expands Global Footprint With New European IDMO Smart Factory In Leiden 1/16/2026

    Cellares, the first Integrated Development and Manufacturing Organization (IDMO), today announced it has secured a site and signed a long-term lease for a new IDMO Smart Factory at Leiden Bio Science Park (LBSP) with Dura Vermeer Commercieel Vastgoed. The facility will serve as Cellares’ European headquarters and expand the company’s global manufacturing network with dedicated regional capacity.

  8. 3PBIOVIAN Strengthens Its International R&D Positioning With French CIR Certification At Its Sites In Spain And Finland 1/16/2026

    3PBIOVIAN, a leading CDMO in process development and manufacturing of recombinant proteins and advanced therapies, has obtained the French CIR (Crédit d’Impôt Recherche) certification at its two production and development sites: Turku (Finland) and Pamplona (Spain). The certification is valid until 2027 and strengthens the company’s position as a strategic partner for international R&D projects.

  9. Avance Clinical Launches Diversity In STEM Scholarships Across Australia And North America 12/22/2025

    Avance Clinical, the award-winning global CRO for biotechs, has announced the launch of its new Diversity in STEM Scholarships, a global initiative designed to support women and minority-group students pursuing careers in science, technology, engineering, and mathematics (STEM). The program includes dedicated intakes in Australia and the broader Asia-Pacific region, as well as North America, reinforcing the company’s commitment to equity and inclusion in clinical research.

  10. Minaris And Cell And Gene Therapy Catapult Announce Collaboration To Advance Delivery Methods For Cell And Gene Therapies 12/18/2025

    Minaris, a global cell and gene therapy (CGT) contract development and manufacturing organization (CDMO) and multimodality biosafety testing provider and Cell and Gene Therapy Catapult (CGT Catapult), an independent technology and innovation organization specializing in the advancement of the CGT industry, today announced a collaboration to develop CGT delivery technologies to enable more robust manufacturing processes, improved quality, and lower cost of goods.